Nicox SA today announced that Tomas Navratil, PhD, Executive Vice President, Head of R&D of Nicox group, and General Manager of Nicox Ophthalmics, Inc, will present results from the NCX 470 Dolomites phase 2 clinical trial in the session “New Horizons in Pharmaceuticals” at the Glaucoma 360 New Horizons Forum being held on February 7, 2020 in San Francisco.
NCX 470, a second generation nitric oxide (NO)-donating bimatoprost analog for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension, is Nicox’s lead clinical development program. NCX 470 ophthalmic solution 0.065% demonstrated noninferiority and statistical superiority to latanoprost ophthalmic solution 0.005% in the Dolomites trial, a US multicenter, phase 2 safety and efficacy clinical trial.
An end-of-phase 2 meeting with the US FDA is scheduled in Q1 2020. The initiation of the first of two US phase 3 clinical trials (“Mont Blanc”) is expected by the end of Q2 2020.